Below are the financial statements of Tasly Pharmaceutical Group, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of CNY | 2024 2024-01-01 - 2024-12-31 | 2023 2023-01-01 - 2023-12-31 |
|---|---|---|
| Total operating revenue | 8,498.14a | 8,674.01a |
| Operating revenue | 8,498.14a | 8,674.01a |
| Total operating costs | -7,056.79a | -7,232.91a |
| Operating costs | -2,792.25a | -2,880.1a |
| Taxes and surcharges | -125.95a | -128.7a |
| Selling expenses | -2,988.3a | -2,983.53a |
| Administrative expenses | -345.4a | -342.37a |
| Research and development expenses | -830.07a | -917.27a |
| Finance costs | -25.18a | -19.06a |
| Interest expense | -61.28a | -82.52a |
| Interest income | 91.05a | 107.55a |
| Other income | 78.3a | 82.75a |
| Investment income (loss indicated by '-') | -84.4a | -110.92a |
| Investment income from associates and joint ventures | -106.21a | -130.04a |
| Gains on derecognition of financial assets measured at amortized cost | 0.05a | 0a |
| Fair value gains (losses) | -129.05a | -171.88a |
| Credit impairment losses (loss indicated by '-') | -0.62a | -8.19a |
| Asset impairment losses (loss indicated by '-') | -231.77a | -5.12a |
| Gains on disposal of assets (loss indicated by '-') | 2.11a | 0.15a |
| Operating profit (loss) | 1,075.92a | 1,227.88a |
| Non-operating income | 14.48a | 3.06a |
| Non-operating expenses | -21.72a | -9.84a |
| Total profit (loss) | 1,068.69a | 1,221.1a |
| Income tax expense | -209.63a | -204.46a |
| Net profit (loss) | 859.06a | 1,016.64a |
| Net profit (loss) from continuing operations | 859.06a | 1,016.64a |
| Net profit attributable to owners of the parent | 955.59a | 1,071.07a |
| Profit or loss attributable to non-controlling interests | -96.53a | -54.43a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Tasly Pharmaceutical Group’s data sources below and access millions more through our Disclosure Search.